Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA. 2004;291(1):47–53.

Article  PubMed  CAS  Google Scholar 

Beral V, Banks E, Reeves G, Bull D. Breast cancer and hormone-replacement therapy: the million women study. Lancet. 2003;362(9392):1330–1.

Article  Google Scholar 

Støer NC, Vangen S, Singh D, Fortner RT, Hofvind S, Ursin G, et al. Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway. Br J Cancer. 2024;131(1):126–37.

Article  PubMed  PubMed Central  Google Scholar 

Collaborative Group on Hormonal Factors in Breast C. Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence. Lancet. 2019;394(10204):1159–68.

Article  Google Scholar 

Beral V, Peto R, Pirie K, Reeves G. Menopausal hormone therapy and 20-year breast cancer mortality. Lancet. 2019;394(10204):1139.

Article  PubMed  Google Scholar 

Anderson GL, Chlebowsk RT, Aragaki AK, Kuller LH, et al. Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women’s Health Initiative randomised placebo-controlled trial. Lancet Oncol. 2012;13(5):476–86.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chlebowski RT, Anderson GL, Aragaki AK, Manson JE, Stefanick ML, Pan K, et al. Association of menopausal hormone therapy with breast Cancer incidence and mortality during Long-Term follow-up of the women’s Health Initiative Randomized clinical trials. JAMA. 2020;324(4):369–80.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304(15):1684–92.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Pinkerton JV. Hormone therapy for Postmenopausal Women. N Engl J Med. 2020;382(5):446–55.

Article  PubMed  Google Scholar 

Crandall CJ, Mehta JM, Manson JE. Management of Menopausal Symptoms: A Review. Jama. 2023;329(5):405–20.

Article  PubMed  CAS  Google Scholar 

Faubion SS, Crandall CJ, Davis L, et al. The 2022 hormone therapy position statement of The North American. Menopause Soc Menopause. 2022;29(7):767–94.

Article  Google Scholar 

Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091–102.

Article  PubMed  CAS  Google Scholar 

Pinkerton JV, Simon JA, Joffe H, Maki PM, Nappi RE, Panay N, et al. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials. JAMA. 2024;332(16):1343–54.

Article  PubMed  CAS  Google Scholar 

Faubion SS, Shufelt CL, Stefanick ML, Stafford RS. A New Era in Menopause Management? JAMA. 2004;332(16):1335.

Article  Google Scholar 

Anderson GL, Chlebowski RT, Aragaki AK, Kuller LH, Manson JE, Gass M, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women’s Health Initiative randomized trial. JAMA. 2012;290(13):1739–48.

Article  Google Scholar 

Rich-Edwards JW, Corsano KA, Stampfer MJ. Test of the National Death Index and Equifax Nationwide Death Search. Am J Epidemiol. 1994;140(11):1016–9.

Article  PubMed  CAS  Google Scholar 

Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.

Article  PubMed  CAS  Google Scholar 

Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s Health Initiative randomized controlled trial. JAMA. 2004;291(14):1701–12.

Article  PubMed  CAS  Google Scholar 

Chlebowski RT, Anderson G, Manson JE, Pettinger M, Yasmeen S, Lane D, et al. Estrogen alone in postmenopausal women and breast cancer detection by means of mammography and breast biopsy. J Clin Oncol. 2010;28(16):2690–7.

Article  PubMed  PubMed Central  Google Scholar 

Dauphine C, Moazzez A, Neal JC, Chlebowski RT, Ozao-Choy J. Single hormone receptor-positive breast cancers have distinct characteristics and survival. Ann Surg Oncol. 2020;27(12):4687–94.

Article  PubMed  Google Scholar 

Chlebowski RT, Aragaki AK, Pan K, Haque R, Rohan TE, Song M, et al. Menopausal Hormone Therapy and Ovarian and Endometrial Cancers: Long-Term Follow-Up of the Women’s Health Initiative Randomized Trials. J Clin Oncol 2024 Aug. 2024;42(30):3537–49.

CAS  Google Scholar 

McTiernan A, Martin CF, Peck JD, Aragaki AK, Chlebowski RT, Pisano ED, et al. Estrogen-plus-progestin use and mammographic density in postmenopausal women: women’s Health Initiative randomized trial. J Natl Cancer Inst. 2005;97(18):1366–76.

Article  PubMed  CAS  Google Scholar 

Chlebowski RT, Anderson G, Pettinger M, Lane D, Langer RD, Gilligan MA, et al. Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med. 2008;168(4):370–7. quiz 45.

Article  PubMed  CAS  Google Scholar 

Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women’s. Health Initiative Randomized Trials JAMA. 2017;318(10):927–38.

PubMed  Google Scholar 

Pan K, Lavasani S, Aragaki AK, Chlebowski RT. Estrogen therapy and breast cancer in randomized clinical trials: a narrative review. Menopause. 2022;29(9):1086–92.

Article  PubMed  Google Scholar 

Chlebowski R, Aragaki AK, Pan K, Mortimer JE, Johnson KC, Wactawski-Wende J, et al. Randomized trials of estrogen-alone and breast cancer incidence: a meta-analysis. Breast Cancer Res Treat. 2024;206(1):177–84.

Article  PubMed  CAS  Google Scholar 

Harman SM, Brinton EA, Cedars M, Lobo R, Manson JE, Merriam GR, et al. KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric. 2005;8(1):3–12.

Article  PubMed  CAS  Google Scholar 

Prentice RL, Aragaki AK, Chlebowski RT, Rossouw JE, Anderson GL, Stefanick ML, et al. Randomized trial evaluation of the benefits and risks of menopausal hormone therapy among women 50–59 years of age. Am J Epidemiol. 2021;190(3):365–75.

Article  PubMed  Google Scholar 

Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the women’s Health Initiative Randomized Trial. JAMA. 2003;289(24):3243–53.

Article  PubMed  CAS  Google Scholar 

Vickers MR, MacLennan AH, Lawton B, Ford D, Martin J, Meredith SK, et al. Main morbidities recorded in the women’s international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women. BMJ. 2007;335(7613):239.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Bluming AZ, Tavris C. Hormone replacement therapy: real concerns and false alarms. Cancer J. 2009;15(2):93–104.

Article  PubMed  Google Scholar 

Tan DA, Dayu ARB. Menopausal hormone therapy: why we should no longer be afraid of the breast cancer risk. Climacteric. 2022;25(4):362–8.

Article  PubMed  CAS  Google Scholar 

Chlebowski RT, Aragaki AK. Long-term breast cancer incidence trends by mammography, obesity, and menopausal hormone therapy. Breast Cancer Res Treat. 2024;203(1):121–4.